Logistic, ethical, and political dimensions of stepped wedge trials: critical review and case studies. by Prost, Audrey et al.
Prost, A; Binik, A; Abubakar, I; Roy, A; De Allegri, M; Mouchoux,
C; Dreischulte, T; Ayles, H; Lewis, JJ; Osrin, D (2015) Logistic, eth-
ical, and political dimensions of stepped wedge trials: critical review
and case studies. Trials, 16 (1). p. 351. ISSN 1745-6215 DOI:
10.1186/s13063-015-0837-4
Downloaded from: http://researchonline.lshtm.ac.uk/2281275/
DOI: 10.1186/s13063-015-0837-4
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH Open Access
Logistic, ethical, and political dimensions of
stepped wedge trials: critical review and
case studies
Audrey Prost1*, Ariella Binik2, Ibrahim Abubakar3, Anjana Roy3, Manuela De Allegri4, Christelle Mouchoux5,
Tobias Dreischulte6, Helen Ayles7, James J. Lewis7 and David Osrin1
Abstract
Background: Three arguments are usually invoked in favour of stepped wedge cluster randomised controlled trials:
the logistic convenience of implementing an intervention in phases, the ethical benefit of providing the intervention
to all clusters, and the potential to enhance the social acceptability of cluster randomised controlled trials. Are these
alleged benefits real? We explored the logistic, ethical, and political dimensions of stepped wedge trials using case
studies of six recent evaluations.
Methods: We identified completed or ongoing stepped wedge evaluations using two systematic reviews. We then
purposively selected six with a focus on public health in high, middle, and low-income settings. We interviewed their
authors about the logistic, ethical, and social issues faced by their teams. Two authors reviewed interview transcripts,
identified emerging issues through qualitative thematic analysis, reflected upon them in the context of the literature,
and invited all participants to co-author the manuscript.
Results: Our analysis raises three main points. First, the phased implementation of interventions can alleviate problems
linked to simultaneous roll-out, but also brings new challenges. Issues to consider include the feasibility of organising
intervention activities according to a randomised sequence, estimating time lags in implementation and effects, and
accommodating policy changes during the trial period. Second, stepped wedge trials, like parallel cluster trials, require
equipoise: without it, randomising participants to a control condition, even for a short time, remains problematic. In
stepped wedge trials, equipoise is likely to lie in the degree of effect, effectiveness in a specific operational milieu, and
the balance of benefit and harm, including the social value of better evaluation. Third, the strongest arguments for a
stepped wedge design are logistic and political rather than ethical. The design is advantageous when simultaneous
roll-out is impractical and when it increases the acceptability of using counterfactuals.
Conclusions: The logistic convenience of phased implementation is context-dependent, and may be vitiated by the
additional requirements of phasing. The potential for stepped wedge trials to enhance the social acceptability of
cluster randomised trials is real, but their ethical legitimacy still rests on demonstrating equipoise and its configuration
for each research question and setting.
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Background
Stepped wedge trials are a type of cluster randomised
controlled trial in which clusters are randomised to re-
ceive an intervention at different start times, and all
clusters eventually receive it. Arguments for stepped
wedge trials (henceforth referred to as SWT) fall into
three broad categories. The first relates to logistic
benefits: phased implementation of an intervention is
advantageous when it is infeasible or impractical to
introduce it in a large number of clusters simultan-
eously [4, 9, 27, 29, 46]. The second argument relates
to ethical benefits. The fact that all clusters eventually
receive the intervention is thought to alleviate concerns
about denying benefits to control groups, especially
when evidence suggests that the intervention is likely
to have a positive effect compared to current practice
[9]. A third, related, argument is that introducing an
intervention to all clusters over time may make cluster
randomised controlled trials (CRT) more socially ac-
ceptable, particularly in the context of implementation
research nested within ongoing health programmes, or
when further evidence is sought about an already ac-
cepted policy [52].
Despite these perceived benefits, SWT face criti-
cisms. Some researchers argue that they are particu-
larly susceptible to bias introduced through secular
changes in main outcomes and usually take longer
than parallel group trials to achieve equivalent statis-
tical power [29, 39]. Others contend that they pose a
greater risk of attrition than parallel group trials, and
that it is difficult to justify the ethics and costs of de-
livering an intervention to all clusters if it is proven in-
effective in the final analysis [39].
Previous discussions of the benefits and drawbacks
of the stepped wedge design have tended to focus
mainly on its statistical efficiency and analytical re-
quirements. With notable exceptions, including the
work of Kotz et al. [39], assumptions about its logistic,
ethical, and political dimensions have generally been
examined in theoretical rather than pragmatic terms.
Are the alleged logistic, ethical, and political benefits
of stepped wedge trials real or assumed? In this article,
we explore the reality of implementing such trials,
their ethical and political dimensions. We used data
from the review conducted from this series [4], and ex-
amined six case studies of recent evaluations [14, 17,
35, 50, 58, 63].
Methods
This article is part of a broader series on stepped wedge
trials. We examined reasons for conducting SWT re-
ported in studies published between 2010 and 2014 [4,
9, 46]. We then reviewed completed or ongoing trials
to identify potential case studies, using the review
published by Mdege et al., which included SWT pub-
lished up till 2010, and the review by Beard et al. in-
cluded in this collection [4, 46]. We did not use
predefined inclusion or exclusion criteria to select case
studies. Instead, the studies were purposively chosen to
span a range of public health interventions and to in-
clude high-income and low-income settings. Drawing
upon case-study approaches, two authors (AP and DO)
interviewed the study authors and discussed their ra-
tionale for choosing a stepped wedge design, logistic is-
sues faced during implementation, and ethical benefits
and drawbacks [12]. We reviewed the interview tran-
scripts, identified emerging issues through qualitative
thematic analysis, reflected upon them in the context of
the literature, and invited all participants to comment
on the manuscript as co-authors [59, 60]. We obtained
informed consent from all participants. As participants
were considered to be ‘key informants’ and participated
in reviewing drafts of the article as co-authors, no spe-
cific ethical approval was required or obtained for this
work.
Results
Table 1 summarises the characteristics of the stepped
wedge evaluations in which six co-authors participated
(IA, AR, MDA, CM, TD, HA). Two were conducted in
the UK, one in France, two in Zambia, and one in
Burkina Faso. Three studies tested complex interven-
tions to improve the quality of care in health facilities:
the Data-driven Quality Improvement in Primary Care
(DQIP) study in general practice surgeries in the UK,
the CONFUCIUS study in French surgical wards, and
the BHOMA study in Zambian primary health centres
[17, 50, 63]. One study tested the effect of introducing
routine HIV testing at tuberculosis clinics in London,
UK [35, 58]. Another assessed the effect of community
health insurance on access to care and household spend-
ing in Burkina Faso [14]. Finally, a non-randomised
stepped wedge evaluation compared two ways of deliver-
ing antiretroviral therapy for HIV to pregnant women in
Zambia [35].
Logistic features
Phased implementation: useful but not necessarily easy
‘My own personal perspective is that this is quite a se-
ductive design, because of the practical aspects, the fact
that everybody gets the intervention, the fact that you
can look at the effect of time on the impact of the inter-
vention. The big caveat is that it requires ‘extreme
coordination’ to achieve all the different tasks. In each
step, you have to ensure that each clinical service has
included enough patients, because otherwise you miss
out… So you have very rigorous parameters to abide by.
And that, for me, is the only drawback’. (Interview 5)
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Table 1 Characteristics of trials led by the authors
Lead author Country Clusters Intervention Main outcome(s) Interview number
De Allegri [14] Burkina Faso 33 geographical rural
and urban clusters
• Offer of community health insurance Health service utilization 1
Dreischulte [17] (DQIP
study)
United Kingdom 40 general practice
surgeries in two Scottish
health boards
• Each practice received a visit providing education on targeted
prescribing and training in the use of an informatics tool
Composite measure of high-
risk prescribing
2
• The informatics tool provided weekly updated feedback of targeted
prescribing at practice level, prompting the review of individual clients
affected, and summarising each patient’s relevant risk factors and
prescriptions
• Payments for practices: a US $560 upfront incentive and US $24 for
each client reviewed during the intervention
Killam [35] Zambia Antenatal care clinics • Antiretroviral therapy for HIV during antenatal care Proportion of treatment-
eligible women initiating
antiretroviral therapy during
pregnancy
3
Roy [58] United Kingdom Tuberculosis clinics in
London
• Universal offer of HIV testing in tuberculosis clinics Levels of HIV test offers,
acceptance and coverage
4
Mouchoux [50]
(CONFUCIUS study)
France Three surgical wards • Preoperative geriatric consultation Postoperative delirium within
seven days of surgery
5
• Training of ward staff and Hospital Elder Life Program
• Conferences about cases of delirium
Stringer [63]
(BHOMA study)
Zambia Catchment areas of
primary health care
centres
• Implementation of clinical protocols, forms, and systems by
Quality Improvement (QI) team in primary health centres.
Overall mortality 6
Under-five mortality
• Monitoring of care and mentoring facility staff to improve quality.
• Engagement of community health workers to refer and follow up clients.
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‘As soon as you randomise the practices, you need to
basically get a date in your diary when you initiate the
intervention. And we were struggling at the beginning -
because the practices were busy’. (Interview 2)
In 20 of the 37 SWT reviewed for this series, and in
all six case studies, the possibility of implementing the
intervention in phases was either the main or an import-
ant reason for choosing the design [2, 5, 6, 8, 13, 17, 19,
23, 36, 37, 43, 50, 54, 56, 61]. In Burkina Faso, the com-
munity health insurance scheme being tested could not
logistically have been implemented in all clusters at
once; neither could the quality-improvement interven-
tion implemented in one of the two Zambian trials [14,
63]. In the non-randomised stepped wedge evaluation of
antiretroviral provision in Zambian antenatal clinics,
phased implementation was desirable because there were
substantial differences in clinic size and patient num-
bers, and the intervention team wanted to begin with
smaller clinics before tackling larger ones [35]. Logistics
also have ethical implications: if it is unfeasible or very
challenging for an organisation to roll out an interven-
tion throughout an area or health service, it is likely that
a better intervention will be delivered by phasing its
implementation.
However, phasing the intervention and adhering to
randomised implementation schedules often introduced
new challenges. In the case of complex interventions
with multiple components, it typically meant scheduling
several rounds of training activities. Five of our six case
studies took place within health systems, and phased im-
plementation was challenging when communicating with
busy clinical teams who needed advance warning to take
part in any research activity [17, 35, 50, 58, 63]. In
addition, intervention teams often had to wait and check
if the required number of patients had been recruited in
each step before proceeding to the next one, leading to
cumulative delays. Planning for these additional logistic
challenges is therefore critical for teams thinking of
embarking on SWT. Researchers should also consider that
phased implementation is possible within the context of
parallel cluster RCT, and that examples of this are now
available [39, 47, 49].
Variability of implementation intensity over time
‘The way this was worked out was that there were
intervention teams in each district and so they
worked with (…) the first step of facilities. They did
on-site training and on-site mentoring, and then the
frequency of mentoring reduced. And then six months
later they had to start the next group of six… And so
ultimately, of course, as time passes they have more
and more things to do and eventually less and less
time for the new facilities coming in. Although they
may get better at doing it, because they have more ex-
perience…’ (Interview 6)
In lengthy trials of interventions with heavy training or
support components, the intensity with which an inter-
vention is delivered may vary over time. For example,
the workload of intervention teams may increase as
more clusters step into the intervention period [50, 63].
In the BHOMA trial, the quality improvement interven-
tion included an initial training followed by ongoing
mentoring using review of primary health centre data,
and the intervention team had a heavier workload to-
wards the end [63]. We think that the consequences of
such effects are largely trial-specific. In some studies,
phased implementation led to increased intensity as
teams become better at delivering the intervention; in
others, accumulating workload caused intervention fatigue
and a decrease in intensity. It may be possible to docu-
ment this by collecting data on specific features of the
intervention (coverage or quality measures, for example)
to quantify and model the intervention’s intensity and its
relationship with outcomes of interest (although published
trials show few examples of this) [4].
Changes in intervention models on the basis of experience
‘So the argument was always given as, ‘well, we would
have never managed to do everywhere at once, so we
randomly picked some villages from where to start,
and this will also helps us to better understand if it
works or not, and learn about the process along the
way to make sure that by the time it comes to your
village, the insurance scheme runs better than when
we started’. Because, obviously, we also adjusted the
scheme as we moved along. Small things in the
communication campaign, in the organization and so
on’. (Interview 1)
‘In a stepped wedge, you have more opportunity to
learn from what may have gone wrong previously. Or
in our case we could see ‘run-charts’ of the practices,
and at least get an estimate of whether it worked, so
there would have been temptation in case it didn’t
work, that we would tweak the intervention or try to
make it better. So we had a protocol for what we
would do in each practice at each point in time to
avoid that’. (Interview 2)
‘There has to be a logically acceptable margin of
variability for the intervention. (…) If it’s a drug, that’s
not a problem. But if people need to be sensitised,
trained… well, people don’t all react the same. In our
study about falls (in the elderly), towards the end, we
had a meeting of all the participating clinics, which
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was really about sharing experiences… We asked
them ‘how did you set up the intervention?’, ‘what
happened afterwards?’, ‘what did you create together?’
Members of the clinical teams shared their
experiences. That created a kind of dynamic, you
see… Each team took ownership of the intervention,
but they did this in different ways, and so there will
always be the introduction of random variability. And
that is extraordinary… That’s the richness of it all…
That's what makes it worth it. But of course for
‘methodological purists’ that’s no good at all, it’s not
measurable, it introduces variability. But it’s not like ‘I
take a drug or I don’t take it’, I receive an
intervention, I take it, appropriate it, and I implement
it with degrees of variation. (…) The paradox with
these kinds of interventions is that they have to be
somewhat regulated, but if people do not own them
they will never be used later on, for real, and they will
never be effective. People need to have that margin of
appropriation, of adaptation. If they don’t have it, the
battle is lost’. (Interview 5)
Guidelines for the development of complex interven-
tions emphasise the need to define and protocolise
activities before their implementation in order to stand-
ardise delivery and enhance replicability [11]. However,
SWT are often conducted by teams with strong inter-
ests in ‘real world’ operational research, which is neces-
sarily inflected by a preference for ‘learning by doing’.
Many trials of complex interventions also face unfore-
seen events because processes are never as controlled
in reality as they are in a laboratory [57]. Because SWT
involve phased implementation and sometimes build
upon routinely collected data, teams may face a tension
between protocolising interventions and adapting them
as they go along. For example, the DQIP intervention
team was not blinded to allocation and could develop a
sense of whether it was working from data on the per-
formance of participating surgeries. This made it more
tempting to ‘tweak’ the intervention in case it did not
work. To remedy this, they put in place a protocol
recommending actions at each point in the data collec-
tion process [17]. ‘Tweaking’ did take place in the Bur-
kina Faso intervention: the core of the intervention
(insurance) did not change over the trial period, but the
communication campaign to promote it evolved over
time, with the possibility that this may have affected
the trial’s outcomes [14]. As a group, we think that it is
important to protocolise complex interventions at the
beginning, but with the understanding that tweaking or
refining - rather than entirely redesigning - might
occur; this tweaking can be documented, and, for some
interventions, is necessary to ensure local ownership
and long-term sustainability.
Changes in policy and clinical guidelines
‘We also planned another stepped wedge trial, and we
had funding for it, but we had to give the money back
because in the meantime there was a competing
intervention started by the health board where we
wanted to do the trial, and so that meant that we just
couldn’t do it. That would also not be great in a two-
arm trial, but it may be particularly bad in a stepped
wedge trial’. (Interview 2)
Another concern linked with phased implementation is
the possibility of policy or clinical guidelines changing
during the study timeframe. This has potentially more ser-
ious consequences for a SWT than for a parallel CRT: in a
parallel CRT, the introduction of a new policy is
significant, but would be expected to influence both inter-
vention and control clusters in the same manner. In a
SWT, the policy change could change the outcome of the
trial dramatically, depending on the proportion of clusters
that have crossed over into the intervention phase. For ex-
ample, the threshold CD4 count for antiretroviral eligibil-
ity changed during the study conducted in antenatal
clinics in Zambia [35]. In this case, the researchers de-
cided to maintain the previous treatment eligibility cut-off
for the evaluation. However, such a decision may not al-
ways be possible if the change is mandatory. In some cases
the timeframe for completing a stepped wedge trial might
also be extended to a duration that compromises the use-
fulness of its findings: practice may change, guidelines
may evolve, or there may be concerns about changing the
intervention to reflect new knowledge without vitiating
the purpose of the study design.
Attrition
Some researchers have suggested that when geographical
clusters or health facilities consent to participate in a
stepped wedge trial and are randomised to a later interven-
tion start date, they may lose interest and drop out [18].
To prevent this, some intervention teams have actively
developed strategies to keep clusters engaged in their trials.
For example, the DQIP intervention team gave a one-off
financial incentive in line with local research governance
regulations to all participating healthcare practices, and
also kept them informed of the progress of the study with
newsletters [17]. The CONFUCIUS study team organised
regular pre-intervention meetings with clusters (surgical
wards) in control phases to keep them engaged [50]. Of
the 10 stepped wedge trials completed between 2010 and
2014 included in the review conducted for this series, only
one lost clusters to follow-up (three of 68 households re-
cruited). This suggests that there is probably no increased
risk of attrition with this design [4, 28].
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Lags in implementation and effect
‘We were trying to see how long it takes after a site
‘steps in’, to when you can consider that the
intervention is fully implemented, because that lag
time is quite important to calculate’. (Interview 6)
‘What we did for our study on falls, where the
intervention was a program of training and reflection
within the clinical service, was to use what we called
‘transition time’, that is, we didn’t consider that the
entire clinical service was trained after the main
referring staff had been trained. We couldn’t assume
that… So we told them, ‘you have three months to set
things up’, and then we considered that the clinical
team was trained up’. (Interview 5)
How does one decide that a cluster - a group of people
or a health facility - is fully in receipt of an intervention,
and when it can realistically be expected to have
‘worked’? These questions are especially complicated
when interventions have multiple components and may
take time to be internalised. The issues are common to
individually randomised trials, SWT and parallel group
CRT [27]. Two typical solutions are to wait until all
training components have been delivered, and to allow
groups a lag time to settle into the intervention, after
which they are considered part of an intervention ‘step’.
In common with other CRT, researchers may also fac-
tor in a lag in order to allow time for a plausible
population-level effect to be observed. Quantifying this
time-to-effect can be difficult. The BHOMA team found
it challenging to determine how long after their quality
of care intervention they might realistically expect an ef-
fect of the intervention and an effect on adult mortality.
This led them to suggest that stepped wedge designs
might be better suited to measuring the effects of inter-
ventions with shorter rather than longer lag effects.
The phased implementation implied by SWT requires
careful planning: approaching geographic clusters or
clinics, collecting data, implementing the intervention,
keeping control clusters engaged enough to stay in the
trial, and considering the impact of lag times on sample
size requirements, analyses, duration, and cost. On bal-
ance, both simultaneous and phased implementation
pose challenges that need to be appraised on a case-by-
case basis, and it is not entirely clear that SWT win in
terms of logistic convenience.
Ethical dimensions
‘Really, the expectation was that whatever we were
doing we would be improving things (…) and so they
were less keen for us to do it where we had some
primary care centres that didn’t get the intervention’.
(Interview 6)
‘This thing that all practices were to get the
intervention, that was attractive. That was probably
the most attractive about it’. (Interview 2)
‘… If I was working on something else or working on
the implementation of performance-based financing
or a malaria control campaign, then I would still say,
‘that’s really an interesting design, and it makes
everybody quite happy because in the end (…)
everybody gets the intervention and it’s easier to justify
than keeping some people constantly as controls’.
(Interview 1)
SWT are subject to the same foundational ethical prin-
ciples as all clinical research: respect for persons, benefi-
cence, justice, and respect for communities [67]. In
addition, a range of specific ethical considerations - in-
cluding the identification of the trial ‘subject’, the need
for informed consent [38], the potential role of cluster
gatekeepers, and the protection of vulnerable popula-
tions [16, 20, 24, 31, 44, 45, 67] are common to both
stepped wedge and parallel CRT.
In this section, we examine ethical questions that are
of particular concern to the stepped-wedge CRT. First,
we consider whether the evidence in favour of the ex-
perimental intervention raises concerns about the ethical
permissibility of the SWT design (or concerns about the
applicability of our current ethical principles for the
assessment of the SWT). Second, we consider whether
the idea that providing control subjects with an inter-
vention eventually - that is, delaying its provision to con-
trol groups - is a persuasive reason to favour the SWT
over other trial designs.
Evidence and equipoise
First, the SWT design is based on the idea that an inter-
vention is likely to be effective, and therefore aims to
end with the implementation of the intervention. In
other words, whether implemented on the basis of new
guidelines or on the basis of researchers’ beliefs, the in-
terventions that have been tested in SWT tend to have
been accompanied by some conviction that they will do
good, and there is a sense that the balance of opinion
falls further away from ‘equally distributed uncertainty’
than it does in parallel group trials [1, 3, 7, 10, 15, 22,
25, 26, 33, 34, 41, 48, 51, 62, 64–66]. Implementers used
expressions such as ‘we thought it was good, but we
didn’t know how good’ (Interview 2), or ‘We felt that it
was going to be successful’ (Interview 5).
The balance of evidence in favour of the intervention in a
SWT raises an interesting ethical tension. The ethical
Prost et al. Trials  (2015) 16:351 Page 6 of 11
permissibility of a trial is often thought to depend, at least in
part, on the existence of a state of equipoise [32]. That is,
equipoise depends on uncertainty or disagreement [3, 10, 22,
25, 34, 51, 65]. But, as the quotations above illustrate,
interventions examined using SWT seem likely to be
beneficial [13, 25, 34, 62, 65]. This is problematic be-
cause if equipoise has already been disturbed, the trial
does not seem to meet ethical requirements.
How can we resolve this tension? One possible response
is to suggest that equipoise is ill-equipped to assess the
permissibility of a SWT. There is some support for this
position in the literature. Objections to equipoise include
the idea that it has proven hard to delineate and does not
quite fit with a public health perspective [1, 7, 26, 41, 48].
Opinions on the potential benefits of an intervention are
held by researchers (traditionally labelled as the ‘expert’
group), but also by clinicians, policy-makers, and partici-
pants [1, 33, 41, 66]. All four may not agree [66]. Opinions
also change with accrual of information and depend not
only on the efficacy of the intervention, but also on the
trade-off between benefits and harms [41]. Finally, imple-
mentation researchers may feel that equipoise is less of an
issue for them, and that randomisation is simply a way to
ensure fairness in allocation, especially in the context of
scarce resources, and to assess impact more rigorously.
These responses are not persuasive. Equipoise aims to
ensure the appropriate treatment of subjects in all arms
of a trial. It also helps to ensure that subjects in the con-
trol arm are not unduly deprived of the experimental
intervention. Abandoning the requirement of equipoise
would not provide research subjects in SWT with these
protections, and we think that an ethical principle
helping to ensure the appropriate treatment of research
subjects is an important part of the ethical assessment of
the SWT. More generally, abandoning equipoise would
not help to explain when the risks of a stepped wedge
trial stand in reasonable relation to the knowledge to be
gained.
Perhaps a more constructive solution would be to con-
sider whether the evidence in favour of interventions
assessed in an SWT is sufficient to suggest that equi-
poise has been disturbed at the outset. That is, we might
consider the possibility that the intervention under test
may still be either ineffective in a particular setting or
that it may lead to harm, irrespective of an a priori belief
in its benefits. Equipoise may apply despite the fact that
there is confidence that the intervention under test will
‘work’. In the case of a SWT, the uncertainty might lie in
the degree of effect, balance of benefit and harm, cost
utility, or effectiveness in a specific operational milieu or
at scale. For example, implementation of an intervention
might be based on a consensus that it would be beneficial,
but there may be uncertainty about its potential effective-
ness when rolled out in a given institutional and human
resources context. There may also be multiple potential
outcomes. Different aspirations for interventional effect
are common in public health interventions and are influ-
enced by individual and political perspectives [53].
Permissibility of delaying effective treatment
A second ethical question concerns the idea that the
stepped wedge design mitigates concerns about the
appropriate treatment of research subjects, especially
those in the control groups. A perceived advantage of
the design is that control groups are certain to receive
the intervention eventually (although this is so, it glosses
the fact that a given individual in a control group might
not actually receive the intervention, which may happen
before they join or after they leave). This is thought to
address concerns about unjustifiably depriving partici-
pants of the intervention being tested [9, 62]. Thirteen
of the 31 stepped wedge trial results or protocol articles
published between 2010 and 2014 justified their choice
of design by invoking the idea that all clusters would
eventually receive the intervention, and an a priori belief
in its benefit [2, 5, 13, 25, 34, 36, 37, 50, 56, 61, 62, 65].
This raises an important ethical question: if it is im-
permissible to deprive a control group of an interven-
tion, then what, if anything, makes it permissible to
delay the intervention to the same control group? Do
researchers have an ethical mandate to deprive control
groups of an intervention - even for a limited time - in
the interests of testing its effectiveness? There is no
ethical argument to explain why it should be permis-
sible to deprive participants temporarily of an effective
intervention [7]. In the absence of this sort of argu-
ment, we think that delayed access is also problematic.
Other considerations
In a parallel group trial, control groups are protected from
unnecessary roll-out and unpredicted harms. Depending
on the design and duration of the trial, a stepped wedge
design may lead to a minimum quantum of participants
being exposed to the intervention to achieve a parsimoni-
ous evaluation. However, in circumstances in which a
SWT needs a larger sample size or takes longer than a
comparable parallel trial, it will, in fact, expose more
people to the control phase than a parallel group trial,
which is clearly problematic [10].
Conversely, participants in a control group may be
unjustifiably deprived of the benefits of an intervention. If
a parallel group trial confirms the efficacy of an interven-
tion, the intervention would generally merit roll-out and
the existing control group would usually be the first candi-
date for introduction. Here ethics blend with logistics: the
funding and timescale for a trial do not usually allow for
subsequent replication, the trial findings may not be inter-
preted as a mandate for roll-out, and the implementers of
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a trial intervention may not be positioned appropriately to
enact it on a larger scale [51]. Compared with this lack of
assurance, a stepped wedge design can at least guarantee
implementation in control groups.
Given our discussion of the background to imple-
mentation in terms of equipoise, one might argue, on
the other hand, that the stepped wedge design could
protect control groups from receipt of an unsuccessful
intervention. If the analysis of a SWT involves the use
of monitoring data - if it is unblinded and interim ana-
lysis is not restricted as it is in the case of a parallel
group design - it is conceivable that implementers
might stop roll out before control groups have stepped
into the intervention. This would presumably be con-
tingent on similar stopping rules to those applied to
parallel group trials, but it might in some situations
lead to less exposure and, conceivably, less harm if the
intervention has negative effects.
Where does this leave us? Assessing the harms and
benefits of the stepped wedge design raises similar
questions to those arising in parallel CRT and RCT.
We think that justifications based on delayed interven-
tion are unpersuasive. We also think that, like other
RCT, SWT require equipoise: having some evidence in
favour of an intervention does not make the design
impermissible, but requires researchers to be particu-
larly explicit about why equipoise still obtains in light
of existing evidence.
Political dimensions
‘From our perspective in a National Public Health
Centre, when an intervention is rolled out, often there
is some evidence, possibly even from the same setting,
that shows some degree of effectiveness, so it’s a given
that it will be implemented. Or sometimes there is an
a priori belief and you can’t really challenge that, it
will happen anyway. (…) If we believe it works… And
I suppose a lot of stepped-wedge designs are informed
by that… If you are going to do it everywhere then
the choice is either a before-and-after or a stepped
wedge design’. (Interview 4)
In a scenario in which a policy decision has been
taken to implement an intervention, phased, rando-
mised roll-out provides an opportunity for a more
rigorous evaluation than a before-and-after study. This
is a powerful argument in favour of the stepped wedge
design, but, interestingly, it was only invoked in one of
the 31 trials reviewed in this series [19], and one of our
case studies [58].
Instead, the most commonly used argument in favour
of SWT by researchers themselves is that having a tem-
porary control group is more palatable to participants
than completely denying the intervention to the control
group:
‘When you do the type of interventions that I do, in
clinical service improvement, it is difficult to do a
study where you have one arm where nothing is
done, and the other arm where something is done. I
work in geriatrics, often with hospitals that are not
necessarily university hospitals but smaller centres,
so telling them ‘the intervention will be implemented
later in time, but you will get it’ is a good argument.
One day they will have something… Until then they
must be patient, but one day they will have
something… And that is important for clinicians’.
(Interview 5)
‘I think they’ve almost forgotten that it’s a stepped
wedge trial, they just think of it as a rolled out
evaluation. And I see that a lot… I see a lot of people
who talk about stepped wedges… They don’t really
mean it as a stepped wedge trial… I have quite a lot of
people contacting me and saying ‘I want to do a
stepped wedge trial’, but they don’t really want to do
that… What they mean is they want to roll out an
intervention and evaluate it and somehow they want
to do a before-and-after evaluation of a rolled out
thing. But they don’t really want to do it as a randomised
trial (…)’. (Interview 6)
The use of the stepped wedge design may help to re-
assure participants and institutions that they will benefit
from the intervention and that the phasing will be done
fairly, without bias towards particular communities or
facilities, increasing the likelihood that they will agree to
participate [30, 55]. This point is often offered as an
ethical justification for adopting a stepped wedge design,
but is in fact logistic (about avoiding attrition) and
political (about enhancing the social acceptability of trials).
Anthropologists studying the rise of trials argue that
the social, political and economic conditions created
by unequal access to health and research resources and
decision-making power in high-, middle-, or low-
income settings constitute a variable terrain that shifts
the relationships between so-called autonomous re-
search subjects, informed consent, and researchers
[42]. Ethics and methods are modified to fit the experi-
mental data required to construct the ‘theatre of proof ’
of contemporary evaluation through CRT or, for econ-
omists, ‘randomised evaluations’ [40, 42, 68]. For the
sake of discussion, let us call this ‘trial creep’, always
allowing that it may be entirely justifiable from the
perspective of evaluators.
An important question is whether the stepped wedge
design might exacerbate or mitigate the contentious
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effects of trial creep. The increasing use of SWT might
boost the proliferation of trials more generally, espe-
cially in global health research (the thin end of the
wedge, if we may be forgiven for saying so). This is not
just an academic question about the transferability of
methods from clinical research to the evaluation of
complex social interventions, about which much has
been written [11, 53]. One might argue that the push
for randomised evaluations of health and development
interventions raises the possibility that areas and clin-
ical services in low- and middle-income settings might
become sites for poorly justified experimentation, when
resources might be more fairly allocated to simply
providing services. External funders and researchers
might vest limited decision-making power with local
communities and health providers, and a premium on
randomised evaluations might delegitimize alternative
research strategies, particularly the sort of observational
research that local actors might be more comfortable
with. Many of the essential questions for global health
are operational and must be answered against a back-
drop of poverty and deep social inequity. As Farmer ar-
gues, flexibility, understanding context, and ensuring
local ownership are central to answering them [21].
When conducted on sound ethical principles, both
observational research and trials can provide services
that otherwise would not exist and improve health. But
if we want to improve policy and practice through
evaluation, designs such as the stepped wedge which in-
clude counterfactuals and also respond to logistic and
social concerns should be embraced more widely by the
evaluation community. In many contexts they may be
an appropriate response to the challenge of making de-
signs address social and clinical realities. To see them
as subaltern to parallel trials may be to miss the point,
and they might usefully allow more control by local ac-
tors and institutions concerned about denying benefits
to a control group.
Our study has strengths and limitations. It provides an
account of the logistic benefits and drawbacks of SWT
that is grounded in researchers’ own experiences. It also
offers a discussion of the ethics of SWT informed by the
broader literature on trial ethics. The purposive selection
of case studies is a potential limitation. Clearly, the views
of this group of authors may not represent the experi-
ences of all researchers. Our case studies were also lim-
ited to the field of public health and represent only a
certain range of SWT designs. The nature and degree of
evidence required to disturb equipoise in this context
may differ from others.
Conclusions
Our article proposed three main arguments in relation
to the logistics, ethics, and politics of SWT in the real
world. First, the phased implementation of interventions
may alleviate problems linked to simultaneous roll-out,
but also brings new challenges, particularly those linked
to sequential intervention activities, estimating lag times
in implementation and effect, and dealing with changes
in policy during the trial period. Second, SWT do not
release investigators from the duty of equipoise; without
it, randomising participants to a control condition, even
for a short period of time, remains ethically problematic.
For SWT, equipoise is likely to lie in the degree of effect,
balance of benefit and harm, cost utility, or effectiveness
in a specific operational environment. The third, related
point is that the strongest arguments for a stepped
wedge design are logistic and political rather than eth-
ical. The design is advantageous when simultaneous roll-
out is infeasible or impractical, and when it increases the
acceptability of using counterfactuals in domains in
which this is uncommon.
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